{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:30:44Z","timestamp":1758475844674,"version":"3.35.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Busulfan at high doses has been associated with a risk of seizures. Phenytoin has been used traditionally as anti-seizure prophylaxis, and benzodiazepines and levetiracetam have been introduced more recently, providing data from retrospective series. The\u00a0main purpose of this study was to evaluate the effectiveness of oral clonazepam as anti-seizure prophylaxis in adult patients receiving high doses of intravenous busulfan as part of the conditioning regimen for hematopoietic stem cell transplantation. The secondary objectives were\u00a0to determine the feasibility of this regimen and to analyze the adverse events associated with the use of clonazepam.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective, single-center study included 64 adult patients who received conditioning regimens with high doses of intravenous busulfan and anti-seizure prophylaxis with oral clonazepam, at a dose of 1\u00a0mg\/8\u00a0h, from 12\u00a0h before starting treatment with busulfan until 48\u00a0h after ending administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The effectiveness of the prophylaxis was 100%, with no episodes of seizures during busulfan treatment or in the 72\u00a0h afterwards. Treatment was feasible, and oral scheduled administration was completed in all patients. Adverse events that could be associated with clonazepam included the onset of somnolence, dizziness, and confusion, mostly mild.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The oral clonazepam regimen described in this study has been prospectively shown to be an effective, feasible anti-seizure prophylaxis option with manageable toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00257-3","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:02:47Z","timestamp":1738540967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective observational study of oral clonazepam to prevent high-dose busulfan-induced seizures in adult patients"],"prefix":"10.1186","volume":"37","author":[{"given":"Mar\u00eda Sacramento","family":"D\u00edaz-Carrasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"S\u00e1nchez-Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Fern\u00e1ndez-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Olmos-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Espa\u00f1ol-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Espuny-Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"257_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF00558081","volume":"36","author":"M Hassan","year":"1989","unstructured":"M Hassan G Berg H Ehrsson M Ehrnebo I Wallin B Smedmyr 1989 Pharmacokinetic and metabolic studies of high-dose busulphan in adults Eur J Clin Pharmacol 36 525 530 https:\/\/doi.org\/10.1007\/BF00558081","journal-title":"Eur J Clin Pharmacol"},{"key":"257_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.675756","volume":"12","author":"Z Wang","year":"2021","unstructured":"Z Wang M Zhao S Gao 2021 Epileptic seizures after allogeneic hematopoietic stem cell transplantation Front Neurol 12 675756https:\/\/doi.org\/10.3389\/fneur.2021.675756","journal-title":"Front Neurol"},{"key":"257_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","volume":"28","author":"AL Eberly","year":"2008","unstructured":"AL Eberly GD Anderson JS Bubalo JS McCune 2008 Optimal prevention of seizures induced by high-dose busulfan Pharmacotherapy 28 1502 1510 https:\/\/doi.org\/10.1592\/phco.28.12.1502","journal-title":"Pharmacotherapy"},{"key":"257_CR4","first-page":"6203","volume":"50","author":"G Vassal","year":"1990","unstructured":"G Vassal A Deroussent O Hartmann D Challine E Benhamou D Valteau-Couanet 1990 Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study Cancer Res 50 6203 6207","journal-title":"Cancer Res"},{"key":"257_CR5","first-page":"363","volume":"7","author":"R Camara","year":"1991","unstructured":"R Camara JF Tomas A Figuera M Berberana JM Fernandez-Ra\u00f1ada 1991 High dose busulfan and seizures Bone Marrow Transplant 7 363 364","journal-title":"Bone Marrow Transplant"},{"key":"257_CR6","first-page":"2977","volume":"30","author":"E Carreras","year":"2010","unstructured":"E Carreras JY Cahn C Puozzo N Kr\u00f6ger G Sanz A Buzyn 2010 Influence on busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data Anticancer Res 30 2977 2984","journal-title":"Anticancer Res"},{"key":"257_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bmt.1703593","volume":"29","author":"KW Chan","year":"2002","unstructured":"KW Chan CA Mullen LL Worth M Choroszy S Koontz H Tran 2002 Lorazepam for seizure prophylaxis during high-dose busulfan administration Bone Marrow Transplant 29 963 965 https:\/\/doi.org\/10.1038\/sj.bmt.1703593","journal-title":"Bone Marrow Transplant"},{"key":"257_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/bmt.2008.91","volume":"42","author":"D Caselli","year":"2008","unstructured":"D Caselli O Ziino A Bartoli G Santangelo F Vanadia M Aric\u00f2 2008 Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan Bone Marrow Transplant 42 135 136 https:\/\/doi.org\/10.1038\/bmt.2008.91","journal-title":"Bone Marrow Transplant"},{"key":"257_CR9","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","volume":"84","author":"PJ Shaw","year":"1994","unstructured":"PJ Shaw CE Scharping RJ Brian JW Earl 1994 Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia Blood 84 2357 2362 https:\/\/doi.org\/10.1182\/blood.V84.7.2357.2357","journal-title":"Blood"},{"key":"257_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3109\/08880018.2010.496895","volume":"27","author":"AA Hamidieh","year":"2010","unstructured":"AA Hamidieh R Hamedani M Hadjibabaie M Amini S Sadrai A Ghavamzadeh 2010 Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study Pediatr Hematol Oncol 27 529 533 https:\/\/doi.org\/10.3109\/08880018.2010.496895","journal-title":"Pediatr Hematol Oncol"},{"key":"257_CR11","first-page":"532","volume":"80","author":"G Meloni","year":"1995","unstructured":"G Meloni L Nasta RM Pinto A Spalice U Raucci P Iannetti 1995 Clonazepam prophylaxis and busulfan-related myoclonic epilepsy in autografted acute leukemia patients Haematology 80 532 534","journal-title":"Haematology"},{"key":"257_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s12185-019-02637-7","volume":"109","author":"T Nakashima","year":"2019","unstructured":"T Nakashima T Tanaka K Koido Y Nishibuchi H Hashimoto A Ito 2019 Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation Int J Hematol 109 694 699 https:\/\/doi.org\/10.1007\/s12185-019-02637-7","journal-title":"Int J Hematol"},{"key":"257_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00280-018-3659-8","volume":"82","author":"K Akiyama","year":"2018","unstructured":"K Akiyama T Kume M Fukaya I Shiki T Enami R Tatara 2018 Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients Cancer Chemother Pharmacol 82 717 721 https:\/\/doi.org\/10.1007\/s00280-018-3659-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"257_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11096-020-00977-7","volume":"42","author":"C Chaguaceda","year":"2020","unstructured":"C Chaguaceda V Aguilera-Jim\u00e9nez G Gutierrez J Roura G Riu 2020 Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant Int J Clin Pharm 42 351 354 https:\/\/doi.org\/10.1007\/s11096-020-00977-7","journal-title":"Int J Clin Pharm"},{"key":"257_CR15","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.bbmt.2019.03.001","volume":"25","author":"JS McCune","year":"2019","unstructured":"JS McCune T Wang K Bo-Subait M Aljurf A Beitinjaneh J Bubalo 2019 Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan\/cyclophosphamide conditioning Biol Blood Marrow Transplant 25 1424 1431 https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"257_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11096-013-9768-x","volume":"35","author":"MS Diaz-Carrasco","year":"2013","unstructured":"MS Diaz-Carrasco R Olmos M Blanquer J Velasco A S\u00e1nchez-Salinas JM Moraleda 2013 Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan Int J Clin Pharm 35 339 343 https:\/\/doi.org\/10.1007\/s11096-013-9768-x","journal-title":"Int J Clin Pharm"},{"key":"257_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649 655","journal-title":"Am J Clin Oncol"},{"key":"257_CR18","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed 30 Jun 2012."},{"key":"257_CR19","unstructured":"Olsen J. Good epidemiological practice (GEP) IEA guidelines for proper conduct in epidemiologic research. International Epidemiological Association-European Epidemiology Federation. 2007. http:\/\/www.ieaweb.org. Accessed 17 Jan 2011."},{"key":"257_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.bbmt.2013.10.028","volume":"20","author":"D Caselli","year":"2014","unstructured":"D Caselli A Rosati M Faraci M Podda M Ripaldi D Longoni 2014 Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation Biol Blood Marrow Transplant 20 282 285 https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.028","journal-title":"Biol Blood Marrow Transplant"},{"key":"257_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s12185-019-02795-8","volume":"111","author":"SI Tsujimoto","year":"2020","unstructured":"SI Tsujimoto R Shirai T Utano T Osumi K Matsumoto Y Shioda 2020 Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation Int J Hematol 111 463 466 https:\/\/doi.org\/10.1007\/s12185-019-02795-8","journal-title":"Int J Hematol"},{"key":"257_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1078155216651128","volume":"23","author":"AE Floeter","year":"2017","unstructured":"AE Floeter JS McCune 2017 Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients J Oncol Pharm Pract 23 344 349 https:\/\/doi.org\/10.1177\/1078155216651128","journal-title":"J Oncol Pharm Pract"},{"key":"257_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/pbc.24126","volume":"59","author":"S Soni","year":"2012","unstructured":"S Soni M Skeens AM Termuhlen RPS Bajwa TG Gross V Pai 2012 Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation Pediatr Blood Cancer 59 762 764 https:\/\/doi.org\/10.1002\/pbc.24126","journal-title":"Pediatr Blood Cancer"},{"key":"257_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12185-016-2098-8","volume":"104","author":"E Leon-Rodriguez","year":"2016","unstructured":"E Leon-Rodriguez MM Rivera-Franco 2016 Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation Int J Hematol 104 644 646 https:\/\/doi.org\/10.1007\/s12185-016-2098-8","journal-title":"Int J Hematol"},{"key":"257_CR25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/ajh.23270","volume":"87","author":"GJ Ruiz-Arg\u00fcelles","year":"2012","unstructured":"GJ Ruiz-Arg\u00fcelles D Gomez-Almaguer DP Steensma 2012 Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting Am J Hematol 87 941 https:\/\/doi.org\/10.1002\/ajh.23270","journal-title":"Am J Hematol"},{"key":"257_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02413-0","author":"V Domingos","year":"2024","unstructured":"V Domingos K Nezvalova-Henriksen A Dadkhah ME Moreno-Martinez K Ben Hassine V Pires 2024 A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant https:\/\/doi.org\/10.1038\/s41409-024-02413-0","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"257_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/bcpt.13185","volume":"124","author":"MG Kim","year":"2019","unstructured":"MG Kim A Kwak B Choi E Ji JM Oh K Kim 2019 Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: a meta-analysis Basic Clin Pharmacol Toxicol 124 6 691 703 https:\/\/doi.org\/10.1111\/bcpt.13185","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00257-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:02:50Z","timestamp":1738540970000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00257-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00257-3","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was granted by the Ethics Committee of University Hospital Virgen de la Arrixaca (17 February 2014\/SDC-CLO-2013-01). Written informed consent from all included patients was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}